Skip to main content
Published: Jan 31, 2022
OXFORD, UK January 31, 2022 – PrecisionLife Limited, a global techbio company driving precision medicine in chronic disease with AI-led drug discovery, clinical development, and healthcare solutions, announces the first close of its Series A investment round. The financing, which is ongoing, will enable expansion and progression of its extensive and growing pipeline of commercial opportunities targeting complex chronic diseases. The company anticipates the second close of the Series A investment round in the coming months.
The investment will be used to expand the application of PrecisionLife’s combinatorial analytics platform into drug repositioning with the launch of a new Indication Extensions solution which will systematically identify new precision medicine opportunities for existing patented drugs in novel disease areas. This highly valued solution will provide significant near-term revenue opportunities for pharmaceutical companies with major benefits to patients in areas of unmet medical need.
Additionally, the investment will be used to attract key talent, to deliver a series of partnered R&D projects currently in negotiation with international biopharma and healthcare organisations as well as to initiate its own in-house therapeutics pipeline.
Partnered projects under negotiation include R&D research studies into the long-term effects of coronavirus (long COVID), ALS, and multi-target discovery and validation deals with major pharmaceutical companies.
Steve Gardner, CEO of PrecisionLife, said: “The investor interest we have seen is an indication of the appetite for AI-enabled precision medicines and the innovation of our unique analytical platform for mining patient data. 2022 will be a transformational year for PrecisionLife and this first close enables us to keep up our momentum and realise our ambition to transition from an AI R&D services company to an early-stage precision medicine drug discovery and healthcare focused company with a pipeline of partnered and in-house programmes of novel precision therapies and biomarkers.”
2021 was a year of expansion and achievement of key milestones for PrecisionLife bringing the company to an inflection point in its development:
These achievements were recognised by the International Life Science Awards 2021 in which PrecisionLife won Best Chronic Disease R&D Company.
The financing is being co-ordinated by leading specialist life sciences investment banking and corporate advisory firm WG Partners LLP.
PrecisionLife is changing the way the world looks at predicting, preventing, and treating chronic disease. Our proven, patented analysis methodologies generate more insights from patient data than any other approach to understand the real drivers of disease biology at a level of resolution that nobody else can achieve.
These unique disease insights are enabling PrecisionLife and its partners to revolutionize drug discovery with novel targets for areas of unmet medical need, achieve more successful clinical development, and transform healthcare with accurate precision diagnostics and clinical decision support tools. This approach will deliver a new age of better, more personalized therapy options to improve health, for everyone.
PrecisionLife is a private company headquartered near Oxford, UK and operations in Aalborg and Copenhagen, Denmark, Warsaw, Poland and Cambridge, MA, USA.
For more information see www.precisionlife.com
Follow us on LinkedIn (precisionlifeAI) and Twitter (@precisionlifeAI)
Steve Gardner, CEO
T: +44 (0)1865 575170
T: +44 (0)7968 726585
WG Partners LLP
David Wilson, Nigel Barnes, Parthiv Patel
T: +44 (0) 20 3705 9321
Back to news
Back to top
© 1985 – 2022 BioSpace.com. All rights reserved. Powered by Madgex Job Board Software
PrecisionLife announces first close of Series A financing to progress its drug discovery pipeline and commercial partnerships – BioSpace
Skip to main content